Transgene, Novartis deal

Transgene granted Novartis an option to obtain an exclusive, worldwide license to develop and commercialize TG4010 for cancer. Transgene received a $10 million option fee. Transgene will be responsible for a Phase IIb/III trial of TG4010 in patients with non-small cell lung cancer (NSCLC), which is expected to start by year end. Data from the Phase IIb portion of the trial are expected in 1Q12, after which Novartis will have a 90-day period to exercise its option. ...